This technology allows phenotypic screening to discover new compounds and new targets for complex diseases, such as neurodegenerative diseases and cancer
HCS main assets for active cosmetic ingredients
Confirming the efficacy of nutraceuticals and functional food is a key for the development of new compounds. High content in vitro assays play a role in researching and developing new actives ingredients dedicated to human and animals food.
Phenotypic screening by High Content Screening allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity at the early stage of research.
BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
The extracellular matrix (ECM) is known as a molecular network of macromolecules present in all solid tissues (Figure 1), which plays an important role in the growth, migration and differentiation of cells. This ECM is Read more…
There are many things to perform today using Artificial Intelligence (AI), especially in health and drug discovery domains (but only if you understand the technologies!). If you want to improve your knowledge in the field Read more…
We were invited at the workshop organized by SMILL-E (Seeding Microsystems in Medecine in Lille – European-Japanese Technologies against Cancer) and Yncrea during MedFit event last week. This great workshop was about Digital and Micro Read more…
Atopic dermatitis (AD) is a chronic, common inflammatory skin disease affecting 15-20% of children and 1-3% of adults worldwide. Loss of bacterial diversity from excess abundance of Staphylococcus aureus is associated with increased disease severity, Read more…
It was a great pleasure to be invited (thanks to our partner Molecular Devices) to present our work during these 2 events organized by selectBio in Rotterdam: Organoids and Tox Screening Europe 2019 on June Read more…
Elodie, Véronique et Océane ont profité d’un moment très sympathique – et ensoleillé – lors du barbecue du parc Eurasanté ce midi… Merci à tous, et bon week-end 🙂
In the continuity of our scientific reviews about the important roles of Hyaluronic Acid (HA) in extracellular matrix (ECM) and cell behavior, we herein present this recent review describing the structure – function relationship of Read more…
Last week we were pleased to attend the founding congress of STCM (Société de Toxicologie Cellularie et Moléculaire), which was held in FIAP Jean Monnet (Paris). The topic was “Toxicology towards the 3rd dimension“. With Read more…
The founding congress of the french STCM (Société de Toxicologie Cellulaire et Moléculaire) will take place in Paris at the end of this week (13th-14th June, 2019). The theme of this meeting will be “Toxicology Read more…
We will be present this week and next week in Rotterdam, to talk about 3D cell culture and the importance of the microenvironnement in the relevance of in vitro models. As you known, to mimic Read more…
The extracellular matrix (ECM) is a three-dimensional macromolecular network composed of structural proteins (collagens, elastin), adhesion/signalling proteins (fibronectin, laminins), different proteoglycans, glycoproteins and glycosaminoglycans (GAGs). GAGs are structurally complex, but their structure is simply made Read more…
Even if microbiota-relateds treatments are quite recent in the therapeutical field, at least 2,400 clinical trials were launched in 2018! Gut, skin and oncology microbiota will be definitively be the hot topic in the next Read more…
The 16th SFBMEC congress was held last week in Reims: Elodie and Zied attended the meeting to be aware of the last trends in extracellular matrix (ECM) research and industry and medical applications. And they Read more…
Our CDO Grégory was at the Fluorescence Microscopy Worskshop last week at Pasteur Paris to discover new usages and technologies in microscopy. Even if this event was mainly focused on super resolution microscopy, many tips Read more…
Our study director Elodie really enjoyed Vitafoods last week in Geneva, and the welcome she had on the different booths she visited along the three days! The show was very impressive, with a wide variety Read more…
The status of Young Innovative Company (JEI) recognize young companies very active in R&D. this distinction is given by the french ministry of research.
Led by Pr Bertrand Cariou, director of l’institut du thorax*, the project aims at improving the management of hypercholesterolemia by identifying new markers in cardiovascular risk and new targets of LDL-cholesterol metabolism, which plays a central role in the development and progression of cardiovascular diseases.
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.